Mefloquine as a potential drug against multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1503-1505

  Krieger, David ^a   Vesenbeckh, Silvan ^a   Schönfeld, Nicolas ^a   Bettermann, Gudrun ^a   Bauer, Torsten Thomas ^a,b   Rüssmann, Holger ^a   Mauch, Harald ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^b Deutsches Zentralkomitee Zur Bekämpfung der Tuberkulose E â Scaron V DZK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MEFLOQUINE; RIFAMPICIN; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIMALARIAL ACTIVITY; BACTERIAL STRAIN; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS; HUMAN; IN VITRO STUDY; LETTER; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84946547350     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00321-2015     Document Type: Letter

References (12)

1. Alsaad N, Wilffert B, van Altena R, et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 884-897.
2. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 430-475.
3. Kunin CM, Ellis WY. Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob Agents Chemother 2000; 44: 848-852.
4. Gonçalves R, Kaiser CR, Lourenço MC, et al. Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113. Bioorg Med Chem 2012; 20: 243-248.
5. Bermudez L, Kolonoski P, Wu M, et al. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 1870-1874.
6. Schönfeld N, Bergmann T, Vesenbeckh S, et al. Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. Lung India 2012; 29: 309-312.
7. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990; 19: 264-279.
8. Wernsdorfer WH, Noedl H, Rendi-Wagner P, et al. Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses. Malar J 2013; 12: 443.
9. Wernsdorfer WH. Antimalarial drugs. Health Co-operation Papers 1997; 15: 151-198.
10. Rendi-WagnerP, Noedl H, Wernsdorfer WH, et al. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 2002; 81: 167-173.
11. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, et al. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 2015; 45: 1119-1131.
12. Bolhuis MS, van der Laan T, Kosterink JGW, et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. Eur Respir J 2014; 44: 808-811.